N
Nathaniel E. Wiest
Researcher at Mayo Clinic
Publications - 11
Citations - 43
Nathaniel E. Wiest is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 5 publications receiving 2 citations.
Papers
More filters
Journal ArticleDOI
S2702 Lactobacillus Sepsis, Endocarditis, and Septic Emboli in a Patient with Ulcerative Colitis Taking Probiotics
TL;DR: In this article , a 69 year-old male presented with 1-week of fevers, fatigue, and arthralgias shortly after a 2.5-month course of corticosteroids and intermittent levofloxacin treatments.
Journal ArticleDOI
Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature
Nathaniel E. Wiest,Katherine S. Tzou,Matthew T. Olson,Steven Herchko,Essa M. Bajalia,David D. Thiel,Yanyan Lou,Yujie Zhao,Rami Manochakian +8 more
TL;DR: In this paper, the authors present a case report and review of the literature supporting the hypothesis that CARCs may correlate positively with progression-free survival, and they show that non-small cell lung cancer patients with anaplastic lymphoma kinase or c-ros oncogene 1 mutations who are treated with the tyrosine kinase inhibitor crizotinib rarely develop CARCs.
Journal ArticleDOI
47P Timing of radiotherapy affects outcomes of patients with metastatic NSCLC who receive immunotherapy
S Li,J. V. Inampudi,J. M. Patel,Nathaniel E. Wiest,Tanmayi Pai,Emily B. Butts,Benjamin J McKinley,J. Wang,Guilherme Sacchi De Camargo Correia,Osama Mosalem,Rami Manochakian,Y. M. Zhao,Yiyue Lou +12 more
Journal ArticleDOI
Outcomes of peritoneal metastases in mismatch repair deficient (dMMR) cancers treated with immune checkpoint inhibitors and variables associated with response.
Osama Mosalem,Ahmed Elhariri,Nathaniel E. Wiest,Robin Imperial,Mohamad Bassam Sonbol,Zhaohui Jin,Jeremy Clifton Jones,Jason S. Starr +7 more
TL;DR: In this article , the authors explored the efficacy of immunotherapy in patients with MSI-H/dMMR cancers with peritoneal metastasis (PM) and found that ICI appears particularly effective when tumors exhibit high microsatellite instability (MSI-H) and/or mismatch repair deficient (DMMR) status.
Journal ArticleDOI
Effect of immunotherapy cessation without disease progression on outcomes in patients with metastatic non-small cell lung cancer.
Blake J. McKinley,Shen-yi Li,Nathaniel E. Wiest,Emily Butts,Tanmayi Pai,Jing Wang,Osama Mosalem,Guilherme sacchi De Camargo Correia,Jay Patel,Hiren Koshiya,J. V. Inampudi,Yujie Zhao,Rami Manochakian,Yanyan Lou +13 more
TL;DR: In this paper , the authors conducted a retrospective study of all patients with metastatic non-small cell lung cancer (mNSCLC) treated with immunotherapy at their institution from 2011 to 2022.